These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21865399)

  • 21. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    Li MX; He H; Ruan ZH; Zhu YX; Li RQ; He X; Lan BH; Zhang ZM; Liu GD; Xiao HL; Wu Y; Zhu B; Wang G; Yang ZZ
    BMC Cancer; 2017 Apr; 17(1):245. PubMed ID: 28376735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
    Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
    Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
    Lee SM; Lewanski CR; Counsell N; Ottensmeier C; Bates A; Patel N; Wadsworth C; Ngai Y; Hackshaw A; Faivre-Finn C
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25031274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
    Yu M; Zhao Q; Li Y; Zhang S; Xu Y; Gong Y; Zhu J; Ding Z; Wang J; Peng F; Wang Y; Huang M; Ren L; Lu Y; Liu Y
    Cancer Biother Radiopharm; 2018 Dec; 33(10):421-426. PubMed ID: 31050549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
    J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Ahluwalia MS; Becker K; Levy BP
    Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
    Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
    Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
    Yu HA; Arcila ME; Hellmann MD; Kris MG; Ladanyi M; Riely GJ
    Ann Oncol; 2014 Feb; 25(2):423-8. PubMed ID: 24478319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
    Nosaki K; Yamanaka T; Hamada A; Shiraishi Y; Harada T; Himeji D; Kitazaki T; Ebi N; Shimose T; Seto T; Takenoyama M; Sugio K
    Oncologist; 2020 Dec; 25(12):e1869-e1878. PubMed ID: 32654250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.